We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Three-month ad interim analysis of total anti-SARS-CoV-2 antibodies in healthy recipient of a single BNT162b2 vaccine booster.
- Authors
Salvagno, Gian Luca; Henry, Brandon M.; Pighi, Laura; De Nitto, Simone; Gianfilippi, Gianluca; Lippi, Giuseppe
- Abstract
In multiple linear regression analysis both 1-month post-booster antibodies values (p<0.001) and age (p=0.004) remained negatively associated with the percentage decrease of total anti-SARS-CoV-2 antibodies measured 1 and 3 months after the booster. Keywords: antibodies; COVID-19; immune response; SARS-CoV-2; vaccination EN antibodies COVID-19 immune response SARS-CoV-2 vaccination e181 e183 3 06/21/22 20220701 NES 220701 To the Editor, Although widespread vaccination for preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) complications is now universally considered a highly effective and safe anti-pandemic strategy, vaccine efficacy has been clearly shown to wane over time, thus paving the way to administration of an additional (so-called "booster") dose after completing the primary vaccination cycle [[1]]. Nonetheless, recent evidence suggests that even the vaccine booster-elicited humoral immunity against SARS-CoV-2 wanes over time, such that the administration of additional booster doses has already been initiated in certain countries, with preliminary evidence of enhanced protection compared to people who have only received a single vaccine booster [[2]].
- Subjects
BOOSTER vaccines; SARS-CoV-2; COVID-19 vaccines
- Publication
Clinical Chemistry & Laboratory Medicine, 2022, Vol 60, Issue 8, pe181
- ISSN
1434-6621
- Publication type
Article
- DOI
10.1515/cclm-2022-0385